Muangto Teerapat, Chanthasenanont Athita, Lertvutivivat Supapen, Nanthakomon Tongta, Pongrojpaw Densak, Bhamarapravatana Kornkarn, Suwannarurk Komsun
Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital, Bangkok, Thailand E-mail :
Asian Pac J Cancer Prev. 2016;17(9):4409-4413.
Cervical cancer is the second most common of malignancy found in Thai women. Human papillomavirus (HPV) infection is a major cause. The objective of the present study was to evaluate the prevalence of HPV infection and association with abnormal cervical cytology in Thai women.
This study was conducted at the Gynecologic Clinic, Thammasat University, Pathum Thani, Thailand. A total of 2,144 cases who underwent annual cervical cancer screening by co-testing (liquid based cytology and HPV testing, DNA versus mRNA) during the priod from July 2013 to June 2016 were recruited in this study.
Prevalence of positive high risk (HR) HPV DNA and mRNA test were 19.7 and 8.4%, respectively with a statistically significant difference. Majority of cases of abnormal cytology in this study were atypical squamous cells of undetermined significance (ASC-US). In patients with ASC-US, positive HR HPV DNA was greater than in the mRNA group (10.1 and 4.5%, p<0.001). Nonetheless, there was no significant difference in participants with cervical intraepithelial neoplasia (CIN). HPV mRNA test had slightly lower sensitivity but higher negative predictive value (NPV) than the DNA test to detect abnormal cytology during cervical cancer screening (p<0.001). Both HPV test (DNA and mRNA) had equally efficacy to detect high grade precancerous lesion or higher (CIN 2+).
Prevalence of HR HPV DNA and mRNA were 19.7 and 8.4 percent, respectively. NPV of HPV mRNA was higher than DNA test. Both tests had equal efficacy to detect CIN 2+ with sensitivity and specificity of 63% vs 55.7% and 83% vs 92%, respectively.
宫颈癌是泰国女性中第二常见的恶性肿瘤。人乳头瘤病毒(HPV)感染是主要病因。本研究的目的是评估泰国女性中HPV感染的患病率及其与宫颈细胞学异常的相关性。
本研究在泰国巴吞他尼府法政大学妇科诊所进行。2013年7月至2016年6月期间,共有2144例接受联合检测(液基细胞学和HPV检测,DNA检测与mRNA检测)进行年度宫颈癌筛查的病例纳入本研究。
高危(HR)HPV DNA检测和mRNA检测的阳性率分别为19.7%和8.4%,差异有统计学意义。本研究中大多数细胞学异常病例为意义不明确的非典型鳞状细胞(ASC-US)。在ASC-US患者中,HR HPV DNA阳性率高于mRNA组(分别为10.1%和4.5%,p<0.001)。然而,宫颈上皮内瘤变(CIN)患者之间无显著差异。在宫颈癌筛查中,HPV mRNA检测检测细胞学异常的敏感性略低,但阴性预测值(NPV)高于DNA检测(p<0.001)。两种HPV检测(DNA检测和mRNA检测)在检测高级别癌前病变或更高级别病变(CIN 2+)方面具有同等效力。
HR HPV DNA和mRNA的患病率分别为19.7%和8.4%。HPV mRNA的NPV高于DNA检测。两种检测在检测CIN 2+方面具有同等效力,敏感性和特异性分别为63%对55.7%和83%对92%。